The purpose of this review is to evaluate the evidence of the efficacy and safety of Gaviscon, an alginate-containing medication that effectively controls postprandial heartburn and regurgitation by forming a floating raft that acts as a physical barrier between gastric contents and the lower oesophageal sphincter when exposed to gastric acid. The review covers the evidence for use of Gaviscon as a monotherapy, co-prescribed with Proton Pump Inhibitors (PPIs), as a rescue therapy to prevent rebound symptoms in those stopping PPIs, as well as use in pregnant and breast-feeding women.
Please login below to download this issue (PDF)